Study of DV and Toripalimab before surgery for HER2-low breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (DV and Toripalimab) with chemotherapy before surgery for a specific type of breast cancer (HER2-low, HR-negative) that has not spread too far. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- HER2-low breast cancer (IHC 1+ or IHC 2+ with no gene amplification)
- Hormone receptor (HR) negative (ER and PR less than 1%)
- Stage T1cN1-2M0 or T2-3N0-2M0 breast cancer
- No prior systemic treatment for breast cancer (like chemotherapy or hormone therapy)
- Good general health (ECOG performance status 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (disitamab vedotin and toripalimab) followed by chemotherapy before surgery for people with a specific type of breast cancer that is hormone receptor-positive and HER2-low. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of drugs (DV plus pertuzumab, with or without toripalimab) given before surgery for HER2-positive breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This trial tests whether combining the immunotherapy drug toripalimab with targeted radiation can help patients with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. It aims to find a new treatment option for these patients.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.